semaglutide reaction at injection site Dermal Hypersensitivity to Semaglutide: Two Case Reports Semaglutide Rash at Injection Site:

Funding This article was supported by Novo Nordisk, who was provided with the opportunity to perform a medical accuracy review

In January 2025, Novo Nordisk disclosed key findings from the STEP UP study , a Phase IIIb trial within the global STEP program

Bloating and nausea are the most reported symptoms during the 0.5 mg transition, affecting roughly 25 to 30 percent of researchers

Efficacy and safety of oral semaglutide in type 2 diabetes: evidence from the PIONEER programme

Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system

Compounded semaglutide and tirzepatide are not FDA-approved medications